FDA Grants Accelerated Approval to Sevabertinib for Non-Squamous NSCLC By Ogkologos - November 27, 2025 106 0 Facebook Twitter Google+ Pinterest WhatsApp It also approved a companion diagnostic device to aid in detecting HER2 tyrosine kinase domain activating mutations Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Retifanlimab Adding Palbociclib to Maintenance Anti-HER2 and Endocrine Therapies Improves PFS Over Standard Therapy in Patients with HR-positive, HER2-positive MBC FDA Grants Traditional Approval to Pirtobrutinib for Chronic Lymphocytic Leukaemia and Small Lymphocytic Lymphoma MOST POPULAR EMA Recommends Extension of Therapeutic Indications for Zanubrutinib October 26, 2022 Liquid Biopsy May Predict Risk of Breast Cancer Returning Years Later August 15, 2018 The ‘major conditions strategy’: will ministers fail to give cancer the... February 6, 2023 She Faced Breast Cancer At 16 With Little Help From Doctors.... June 21, 2019 Load more HOT NEWS What Are Biosimilars in Cancer Treatment? ESMO-WHO Collaboration in Kazakhstan Yields Evidence-Based Approach for Closing the Gaps... Workout Wednesdays – Chest Exercises Part 2 Becoming My Own Advocate While Living With a Rare Cancer: A...
